Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bio-Techne Corp (NQ: TECH )

71.34 -0.95 (-1.31%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bio-Techne Corp

< Previous 1 2 3 4 Next >
3 Healthcare Stocks That Should Be on Every Investor’s Radar This Fall
The beauty of healthcare stocks is that they tend to do well in most economic conditions because you can’t live without them. 
Via InvestorPlace
Life Science Firm Bio-Techne's Success Formula: Astute Acquisitions Offering Transformation
William Blair has initiated coverage on coverage of Bio-Techne Corp (NASDAQ: TECH) with a 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023
Via Benzinga
Bio-Techne's Ex-Dividend Date Is Thursday, Here's What You Need To Know
Via Benzinga
Nurturing Growth: Bio-Techne Supports Investors with Growing Earnings
Via Benzinga
This Favorable Sign Appears On Bio-Techne's Chart
Via Benzinga
What 4 Analyst Ratings Have To Say About Bio-Techne
Via Benzinga
3 Biotech Stocks to Buy Before the Breakout
Explosive growth and rapid innovation lie ahead for these three biotechnology stocks, making them the ones to watch. 
Via InvestorPlace
Bio-Techne's Acquisition of Lunaphore Expands Its Spatial Biology Offerings
Bio-Techne Corporation (NASDAQ: TECH) has agreed to acquire Lunaphore Inc with  
Via Benzinga
Abcam Downgrade: Analyst Trims Expectations Amid Activist Investor Engagement and Potential Bid Anticipation
RBC Capital Markets has downgraded Abcam PLC (NASDAQ: ABCM) from Outperform to Sector Perform with a price target of $22,  
Via Benzinga
This Analyst With 83% Accuracy Rate Sees Around 11% Upside In Texas Roadhouse - Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts
U.S stocks closed higher on Friday, with the Dow Jones jumping more than 500 points during the session. 
Via Benzinga
Bio-Techne: Q3 Earnings Insights
Via Benzinga
Thursday Is Your Last Chance To Buy Bio-Techne Before The Dividend Payout
Via Benzinga
Analyst Expectations for Bio-Techne's Future
Via Benzinga
Earnings Outlook For Bio-Techne
Via Benzinga
Bio-Techne: Q1 Earnings Insights
Bio-Techne (NASDAQ:TECH) reported its Q1 earnings results on Tuesday, November 1, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
7 Biotech Stocks That Could Cure Your Portfolio Woes
If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill. 
Via InvestorPlace
5 Cheapest Health Care Stocks You Should Think About
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
5 Health Care Stocks That Are Diving - And May Rally
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
5 Most Cheapest Stocks In The Healthcare Sector: Bio-Techne, Mirati Therapeutics And More
The most oversold stocks in the healthcare sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Our 7 Top Biotech Stock Picks for 2023
Following the devastation of Covid-19, there’s greater interest toward medical innovations, thus bolstering biotech stock picks for 2023. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For January 10, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022
Via Benzinga
NexImmune Price Target Cut By 75%, Plus Wells Fargo Lowers PT Price Target On These Stocks
Raymond James cut the price target for NexImmune, Inc. (NASDAQ: NEXI) from $12 to $3. NexImmune shares rose 2.4% to $1.29 in pre-market trading. 
Via Benzinga
Earnings Scheduled For November 1, 2022
Companies Reporting Before The Bell • BP (NYSE:BP) is estimated to report quarterly earnings at $2.07 per share on revenue of $64.76 billion. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 429 stocks made new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  During Friday's session, 574 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  During Wednesday's session, 265 companies made new 52-week lows. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022
Upgrades 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.